<DOC>
	<DOCNO>NCT02928198</DOCNO>
	<brief_summary>The Bifurcation ABSORB OCT Trial prospective , randomize ( 1:1 ) evaluation efficacy performance single ABSORB everolimus elute bioresorbable vascular scaffold provisional strategy treatment ( ) coronary bifurcation lesion ( ) consecutive subject without fenestration towards side branch . Patients include study divide three different cohort : - Cohort A ( patient 1-20 ) : Angiographic FU OCT 12 month . - Cohort B ( patient 21-40 ) : Angiographic FU OCT 24 month . - Cohort C ( patient 41-60 ) : Angiographic FU OCT 36 month . All patient also telephone FU 30 day , 12 , 24 36 month .</brief_summary>
	<brief_title>Bifurcation ABSORB OCT Trial</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<criteria>Subject bifurcation lesion involve sidebranch large 2 mm main branch involvement ( Medina 0,0,1 lesion exclude ) . Subject must agree undergo clinical investigation planrequired followup visit undergo followup angiography optical coherence tomography . Subject able verbally confirm understand he/she his/her legally authorize representative provide write informed consent prior Clinical Investigation related procedure , approve appropriate Ethics Committee . Subject young 18 year age Subject present STEMI Subject true bifurcation lesion priori two scaffold/stent strategy plan . Subject know hypersensitivity contraindication contrast , aspirin , heparin bivalirudin , antiplatelet medication specify use study ( clopidogrel , prasugrel ticagrelor , inclusive ) , everolimus , poly ( Llactide ) , poly ( DLlactide ) , cobalt , chromium , nickel , tungsten , acrylic fluoro polymer contrast sensitivity adequately premedicated . Known renal insufficiency ( eg . estimate Glomerular Filtration Rate ( eGFR ) &lt; 60mL/min/1.73m2 serum creatinine level &gt; 2.5mg/dL subject dialysis ) Subject limited life expectancy le one year . Subject belong vulnerable population ( per investigator 's judgment , e.g. , subordinate hospital staff ) subject unable read write .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Tomography , Optical Coherence</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Cardiac Catheterization</keyword>
	<keyword>Coronary Biovascular Scaffold</keyword>
</DOC>